Wenderow Tal Baruch 4

What Happened Wenderow Tal Baruch, a director of Microbot Medical, was granted 10,000 shares (reported as a derivative award) on April 1, 2026. The award was reported at $0.00 per share, for a reported transaction value of $0 — indicating the shares were issued as a grant/compensatory award rather than a purchase. This is an equity grant, not a sale or open-market purchase, so it typically reflects compensation or a board award rather than a direct market-confidence signal.

Key Details

• Transaction date: 2026-04-01; Form 4 filed: 2026-04-03 (appears timely under the 2-business-day filing rule).
• Transaction type/code: A (Award/Grant); reported as a derivative acquisition.
• Price per share: $0.00; total reported value: $0.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnotes/conditions: No 10b5-1, tax-withholding, or vesting details included in the excerpt — check the full company or Form 4 filing for grant terms or vesting schedule.

Context Derivative awards commonly represent restricted stock, RSUs, or similar equity compensation and may vest over time; the filing here does not specify the exact form or vesting conditions. Because this was an award at no cash cost, it should be viewed as a compensatory issuance rather than an insider purchase; investors may want to review company filings or proxy statements for more detail on the grant’s terms.